HYALURONAN-BASED HYDROGEL SCAFFOLDS - Intelligent Scaffolds for Tissue Engineering and Regenerative Medicine - page 193

applications and target diseases. Novel HA-based hydrogels have to
demonstrate rigorously proven biocompatibility, controlled degra-
dation, specific interaction with cells and ECM components in the
body and subsequent tissue regeneration behavior in biomedical
applications. Since the HA-based hydrogels mentioned in the main
text showed their clinical potentials and advantages, we expect that
researchaboutHAderivertizationandsubsequentHA-basedhydro-
gelforbiomedicalandtherapeuticapplicationswillkeepfocusingon
noveland clinicablemethods of hydrogel fabrication.
Acknowledgments
This research was supported by the Pioneer Research Center Pro-
gram through the National Research Foundation of Korea funded by
theMinistryofEducation,ScienceandTechnology(2011-0001696).
References
1. N. A. Peppas, P. Bures, W. Leobandung, and H. Ichiwaka, Euro. J. Pharm.
Biopharm ., 27 (2000).
2. Wichterleand D.Lim, Nature , 117 (1960).
3. A. S. Hoffman, Adv. Drug Del. Rev. , 3 (2002).
4. N. E. Fedorovich, J. Alblas, J. R. De Wijn, W. E. Hennink, A. J. Verbout, and
W. J. A. Dhert, Tissue Eng. , 1905 (2007).
5. S. R. Van Tomme and W. E. Hennink, Expert Rev. Med. Dev. , 147 (2007).
6. W. E. Hennink and C. F. van Nostrum, Adv. Drug Del. Rev. , 13 (2002).
7. M. S. Kim, D. Y. Kim, S. Y. Jo, H. K. Kang, Y. D. Park, K. B. Lee, I. S. Kim, S. J.
Hwang, and I Noh, Biomater. Res. , 83 (2008).
8. Hatefi and B. Amsden, J. Control. Rel. , 9 (2002).
9. B. Packhaeuser, J. Schnieders, C. G. Oster, and T. Kissel, Euro. J. Pharm.
Biopharm. , 445 (2004).
10. J. D. Kretlow, L. Klouda, and A. G. Mikos, Adv. Drug Del. Rev. , 263 (2007).
11. S. Tanna, M. J. Taylor, T. S. Sahota, and K. Sawicka, Biomaterials , 1586
(2006).
12. N. Kashyap, B. Viswanad, G. Sharma, V. Bhardwaj, P. Ramarao, and M. N.
V. Ravi Kumar, Biomaterials , 2051 (2007).